New Delhi, April 28 -- The price of pretomanid, a key component used in the treatment of drug-resistant tuberculosis (TB), dropped by 25% in April, to less than $1 per day, primarily owing to Indian manufacturers joining in, people familiar with the matter said.
Experts see this as an important development given the pressures on health spending in high-burden countries. Pretomanid is a key component of the BPaL/M, a shorter and more effective regimen that the Union government has also recently introduced in the national TB programme.
TB Alliance, a non-profit that developed pretomanid, in a statement said the price drop of the key drug reflects ongoing efforts by the organisation and its partners "to broaden access and improve affordabili...